NCT03830385招募中2 期
Open-Label, Multicenter, Phase Ⅱ Study Of Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin As First-Line Treatment In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2019年2月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- overall survival
研究概览
简要总结
The purpose of this single arm, phase Ⅱ clinical trail is to determine the safety and efficacy of paclitaxel (albumin bound),bleomycin and cisplatin or carboplatin in the treatment of recurrent Or metastatic squamous cell carcinoma of the head and neck
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •biopsy proved squamous cell carcinoma of the head and neck;
- •stage IVc according to Union for International Cancer Control (UICC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;
- •18 years or older; without other malignancy;
- •proper functioning of the major organs.
排除标准
- •allergic to paclitaxel (albumin bound) or bleomycin or cisplatin or carboplatin ;
- •female within gestation period or lactation;
- •patients received drug of other clinical trial within 3 months
研究组 & 干预措施
Paclitaxel (Albumin Bound),Bleomycin and Cisplatin or
Experimental
干预措施: PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin (Drug)
结局指标
主要结局
overall survival
时间窗: 5 years
overall survival
次要结局
未报告次要终点
研究者
Qingqing Cai
Chief physician
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04769076The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School40
已完成
2 期
Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric CancerStomach and Gastro-Esophageal Junction (GEJ) CancerNCT02251951Hellenic Oncology Research Group39
终止
2 期
Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial CarcinomaBladder CancerNCT00933374Heinrich-Heine University, Duesseldorf28
招募中
2 期
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast CancerPancreatic AdenocarcinomaLung CancerBreast CancerEsophageal CarcinomaCholangiocarcinomaStomach CancerNCT06199895Liu Huang25
终止
2 期
Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast CancerBreast CancerNCT00532285National Cancer Center, Korea44